(Q36329012)

English

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

0 references

1 reference

Europe PubMed Central

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease (English)

1 reference

Europe PubMed Central

13 August 2017

Alzheimer's disease

0 references

quality of life

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

author name string

Takeda A

1

1 reference

Europe PubMed Central

13 August 2017

Loveman E

2

1 reference

Europe PubMed Central

13 August 2017

Clegg A

3

1 reference

Europe PubMed Central

13 August 2017

Kirby J

4

1 reference

Europe PubMed Central

13 August 2017

Picot J

5

1 reference

Europe PubMed Central

13 August 2017

Payne E

6

1 reference

Europe PubMed Central

13 August 2017

Green C

7

1 reference

Europe PubMed Central

13 August 2017

language of work or name

0 references

publication date

1 January 2006

1 reference

Europe PubMed Central

13 August 2017

International Journal of Geriatric Psychiatry

1 reference

Europe PubMed Central

13 August 2017

21

1 reference

Europe PubMed Central

13 August 2017

17-28

1 reference

Europe PubMed Central

13 August 2017

1

1 reference

Europe PubMed Central

13 August 2017

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

21 January 2018

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

21 January 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

21 January 2018

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

21 January 2018

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

21 January 2018

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

21 January 2018

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of NICE guidelines on the diagnosis and treatment of Alzheimer's disease among general medical hospital inpatients.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Donepezil therapy in clinical practice: a randomized crossover study

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic reviews in health care: Assessing the quality of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1402

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/GPS.1402

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36329012&oldid=1626709812"